Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic Cancers

Michael R Abern; John V Dudinec; Brant A Inman

doi:10.1016/j.euf.2022.04.011

Genomic Sequencing Should Not be Part of the Standard of Care for Most Urologic Cancers

Eur Urol Focus. 2022 May;8(3):639-640. doi: 10.1016/j.euf.2022.04.011. Epub 2022 May 7.

Authors

Michael R Abern¹, John V Dudinec², Brant A Inman³

Affiliations

¹ Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.
² Duke University School of Medicine, Duke University, Durham, NC, USA.
³ Division of Urology, Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA. Electronic address: brant.inman@duke.edu.

PMID: 35537938
DOI: 10.1016/j.euf.2022.04.011

Abstract

There are currently few situations in which genomic testing is actionable for genitourinary tumors. Without clear indications or treatment paradigms, genomic sequencing cannot be recommended as a standard of care for genitourinary tumors.

Publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Genomics
Humans
Standard of Care
Urogenital Neoplasms* / diagnosis
Urogenital Neoplasms* / genetics
Urogenital Neoplasms* / therapy
Urologic Neoplasms* / diagnosis
Urologic Neoplasms* / genetics
Urologic Neoplasms* / therapy